This study is testing a drug called TB006 for adults with Autism Spectrum Disorder (ASD). TB006 is a special type of antibody designed to block a protein called Galectin-3 (Gal-3), which is thought to contribute to inflammation in the brain in people with ASD. The researchers believe that by blocking Gal-3, TB006 might help improve core and related symptoms of ASD. You may be able to join if you are between 18 and 35 years old, have a moderate or higher severity of ASD, and speak English. The study plans to enroll 45 participants. Success will be measured by changes in your Childhood Autism Rating Scores (CARS) at 8 and 14 weeks. The current recruitment status is unclear.

Study design

This is a multi-site, 14-week study where participants will be randomly assigned to receive either TB006 or a placebo (an inactive substance) in a 2:1 ratio. It is a double-blind study, meaning neither you nor your doctor will know if you are receiving TB006 or the placebo.

What's involved

You would have assessments at the start of the study (baseline), and again at Week 8 and Week 14. If you receive the placebo, you may have the option to receive TB006 in an open-label extension phase after the initial 14 weeks.

Compensation

Not stated in the trial record.

Follow-up

Your Childhood Autism Rating Scores (CARS) will be measured at Week 8 and Week 14 after starting treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.